Hemophilia
We recommend
Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult patient with hemophilia A and an inhibitor, whose treatment was discontinued due to repeated bleeding episodes with prolonged aPTT.
No content is currently available on this topic.
